FR2824567B1 - Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene - Google Patents

Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Info

Publication number
FR2824567B1
FR2824567B1 FR0106231A FR0106231A FR2824567B1 FR 2824567 B1 FR2824567 B1 FR 2824567B1 FR 0106231 A FR0106231 A FR 0106231A FR 0106231 A FR0106231 A FR 0106231A FR 2824567 B1 FR2824567 B1 FR 2824567B1
Authority
FR
France
Prior art keywords
regulators
obtaining
specific antigen
lymphocytes specific
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0106231A
Other languages
English (en)
French (fr)
Other versions
FR2824567A1 (fr
Inventor
Herve Groux
Francoise Cottrez
Abdelilah Wakkach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0106231A priority Critical patent/FR2824567B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CA2446981A priority patent/CA2446981C/fr
Priority to JP2002589661A priority patent/JP4185366B2/ja
Priority to ES02740789T priority patent/ES2282425T3/es
Priority to PCT/FR2002/001586 priority patent/WO2002092793A1/fr
Priority to EP02740789A priority patent/EP1390474B1/fr
Priority to DE60218302T priority patent/DE60218302T2/de
Priority to DK02740789T priority patent/DK1390474T3/da
Priority to AT02740789T priority patent/ATE354641T1/de
Priority to US10/477,671 priority patent/US8076133B2/en
Publication of FR2824567A1 publication Critical patent/FR2824567A1/fr
Application granted granted Critical
Publication of FR2824567B1 publication Critical patent/FR2824567B1/fr
Priority to US11/928,189 priority patent/US20080233095A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0106231A 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene Expired - Fee Related FR2824567B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0106231A FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
AT02740789T ATE354641T1 (de) 2001-05-11 2002-05-10 Verfahren zur gewinnung antigenspezifischer tr1- regualtorischer lymphozyten
ES02740789T ES2282425T3 (es) 2001-05-11 2002-05-10 Procedimiento de obtencion de linfocitos tr1 reguladores especificos de antigeno.
PCT/FR2002/001586 WO2002092793A1 (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP02740789A EP1390474B1 (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
DE60218302T DE60218302T2 (de) 2001-05-11 2002-05-10 Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten
CA2446981A CA2446981C (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
JP2002589661A JP4185366B2 (ja) 2001-05-11 2002-05-10 抗原−特異的Ｔｒ１リンパ球を得る方法
US10/477,671 US8076133B2 (en) 2001-05-11 2002-05-10 Method for obtaining antigen-specific Tr1 regulatory lymphocytes
DK02740789T DK1390474T3 (da) 2001-05-11 2002-05-10 Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter
US11/928,189 US20080233095A1 (en) 2001-05-11 2007-10-30 Method for obtaining antigen-specific tr1 regulatory lymphocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0106231A FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Publications (2)

Publication Number Publication Date
FR2824567A1 FR2824567A1 (fr) 2002-11-15
FR2824567B1 true FR2824567B1 (fr) 2003-08-08

Family

ID=8863160

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0106231A Expired - Fee Related FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Country Status (10)

Country Link
US (2) US8076133B2 (enExample)
EP (1) EP1390474B1 (enExample)
JP (1) JP4185366B2 (enExample)
AT (1) ATE354641T1 (enExample)
CA (1) CA2446981C (enExample)
DE (1) DE60218302T2 (enExample)
DK (1) DK1390474T3 (enExample)
ES (1) ES2282425T3 (enExample)
FR (1) FR2824567B1 (enExample)
WO (1) WO2002092793A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
CA2469800A1 (en) * 2001-12-21 2003-07-24 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
FR2852967B1 (fr) * 2003-03-26 2007-12-07 Txcell Procede d'obtention de cellules dendritiques et de cellules t
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
WO2005046729A2 (en) * 2003-11-12 2005-05-26 Txcell Use of lipopeptides for activating t lymphocytes through the skin
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
US7985409B2 (en) 2004-08-11 2011-07-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Tr1 cells for use in atherosclerosis
EP1812563B1 (en) * 2004-10-29 2013-04-10 Benaroya Research Institute at Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
ATE513903T1 (de) * 2005-07-01 2011-07-15 Txcell S A Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc
EA015989B1 (ru) * 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
GB0603081D0 (en) * 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
EP2185936A4 (en) * 2007-08-02 2010-08-04 Iss Immune System Stimulation DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE
JP5539886B2 (ja) * 2007-10-17 2014-07-02 ティクセル Ｔｒ１細胞、間葉系幹細胞およびその使用
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
SI2113254T1 (sl) 2008-04-28 2013-01-31 Txcell Sestave za zdravljenje vnetnih avtoimunskih stanj
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
WO2010077634A1 (en) * 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2221364A1 (en) 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
EP2439534A1 (en) 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
BR112013023968A2 (pt) 2011-03-25 2016-12-13 Txcell uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
AU2019269601A1 (en) 2018-05-17 2020-11-26 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
WO2019237378A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种将CD274基因定点整合至Jurkat细胞的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277635B1 (en) * 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
DE69734974D1 (de) * 1996-02-08 2006-02-02 Us Gov Health & Human Serv Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
CA2254975C (en) * 1996-05-23 2008-12-16 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods

Also Published As

Publication number Publication date
EP1390474A1 (fr) 2004-02-25
DE60218302T2 (de) 2007-11-15
JP4185366B2 (ja) 2008-11-26
FR2824567A1 (fr) 2002-11-15
EP1390474B1 (fr) 2007-02-21
US20080233095A1 (en) 2008-09-25
CA2446981C (fr) 2012-03-20
DE60218302D1 (de) 2007-04-05
ES2282425T3 (es) 2007-10-16
DK1390474T3 (da) 2007-07-02
US8076133B2 (en) 2011-12-13
ATE354641T1 (de) 2007-03-15
WO2002092793A1 (fr) 2002-11-21
JP2004526459A (ja) 2004-09-02
US20040191235A1 (en) 2004-09-30
CA2446981A1 (fr) 2003-11-21

Similar Documents

Publication Publication Date Title
FR2824567B1 (fr) Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
JP2004526459A5 (enExample)
ES2182991T3 (es) Metodo para la preparar 3-haloalquil-1h-pirazoles.
AU3889399A (en) Vaccine delivery system
AU2999199A (en) Mesenchymal stem cells as immunosuppressants
AU3666800A (en) System and method for enhancing online support services using natural language interface for searching database
LU91367I2 (fr) Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant
ATE270082T1 (de) Verfahren zur bereitung und transplantation von flachen implantaten und chirurgische geräte dafür
ATE221086T1 (de) Photovernetztes hyaluronsäuregel und verfahren zu dessen herstellung
CA2267235A1 (fr) Dispositif pour l'assemblage et le desassemblage d'un outil avec un porte-outils
GB2326321B (en) Method device, and article of manufacture for neural - network based generation of postlexical pronunciations from lexical pronunciations
DE59607005D1 (de) Steriles tropfbares ophthalmisches gelpräparat und verfahren zu dessen herstellung
WO2003038062A3 (en) Generation of use of tc1 and tc2 cells
ATE343175T1 (de) Dateitransfersystem, vorrichtung, verfahren und computerlesbares medium, das ein dateitransferprogramm speichert
ZA943782B (en) Immortalization of dendritic cells and generation of functional dendritic cell lines fully competent in antigen presentation and initiating primary T cell responses in vivo
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
AU5211200A (en) Method for diminishing specific immune reactions
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
DE59610629D1 (de) Immunogenes konstrukt, verfahren zu dessen herstellung und verwendung als vakzine
ATE205473T1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
BR9910153A (pt) ácido nucléico e polipeptìdeos de cd80 de felino, cd80 de felino, cd28 de felino e ctla-4 de felino
KR100391709B1 (en) Information interchange system for promoting community between family members
Biddison Generation of Continuously Growing B Cell Lines by Epstein‐Barr Virus Transformation
Huang et al. Location–Positioning Tregs to the right place at the right time
Lafferty By his own device.

Legal Events

Date Code Title Description
CL Concession to grant licences
ST Notification of lapse

Effective date: 20110131